FIZE Medical Opens Series B Toward $20 Million Target

FIZE Medical announced the first close of a Series B financing co-led by Asahi Kasei Medical and Rapha Capital Management, saying it has made significant headway toward a $20 million target. The medtech company said proceeds will accelerate FIZE Optima, which uses continuous physiological data to predict fluid-related risks and guide treatment, while strengthening commercial operations. Asahi Kasei Medical, already FIZE kUO’s exclusive distributor in Japan, will also distribute the platform in Europe. The investment expands the Japanese company’s role beyond distribution in fluid management.